Report cover image

Global Human Bacterial Vaccine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 196 Pages
SKU # APRC20361843

Description

Summary

According to APO Research, The global Human Bacterial Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Bacterial Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Human Bacterial Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Human Bacterial Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Human Bacterial Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Human Bacterial Vaccine include Emergent BioSolutions, Mitsubishi Tanabe Pharma, Bayer, GSK, Pfizer, Merck and Sanofi, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Bacterial Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Human Bacterial Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Bacterial Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Bacterial Vaccine revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Human Bacterial Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Human Bacterial Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Human Bacterial Vaccine Segment by Company

Emergent BioSolutions
Mitsubishi Tanabe Pharma
Bayer
GSK
Pfizer
Merck
Sanofi
Human Bacterial Vaccine Segment by Type

Bacillus Anthracis
Haemophilus Influenzae
Salmonella Typhi
Clostridium Tetani
Streptococcus Pneumoniae
Pertussis
Others
Human Bacterial Vaccine Segment by Application

Elderly
Children
Adults
Human Bacterial Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Bacterial Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Bacterial Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Bacterial Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Human Bacterial Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Human Bacterial Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Bacterial Vaccine revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Human Bacterial Vaccine Market by Type
1.2.1 Global Human Bacterial Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Bacillus Anthracis
1.2.3 Haemophilus Influenzae
1.2.4 Salmonella Typhi
1.2.5 Clostridium Tetani
1.2.6 Streptococcus Pneumoniae
1.2.7 Pertussis
1.2.8 Others
1.3 Human Bacterial Vaccine Market by Application
1.3.1 Global Human Bacterial Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Elderly
1.3.3 Children
1.3.4 Adults
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Human Bacterial Vaccine Market Dynamics
2.1 Human Bacterial Vaccine Industry Trends
2.2 Human Bacterial Vaccine Industry Drivers
2.3 Human Bacterial Vaccine Industry Opportunities and Challenges
2.4 Human Bacterial Vaccine Industry Restraints
3 Global Growth Perspective
3.1 Global Human Bacterial Vaccine Market Perspective (2020-2031)
3.2 Global Human Bacterial Vaccine Growth Trends by Region
3.2.1 Global Human Bacterial Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Human Bacterial Vaccine Market Size by Region (2020-2025)
3.2.3 Global Human Bacterial Vaccine Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Human Bacterial Vaccine Revenue by Players
4.1.1 Global Human Bacterial Vaccine Revenue by Players (2020-2025)
4.1.2 Global Human Bacterial Vaccine Revenue Market Share by Players (2020-2025)
4.1.3 Global Human Bacterial Vaccine Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Human Bacterial Vaccine Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Human Bacterial Vaccine Key Players Headquarters & Area Served
4.4 Global Human Bacterial Vaccine Players, Product Type & Application
4.5 Global Human Bacterial Vaccine Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Human Bacterial Vaccine Market CR5 and HHI
4.6.3 2024 Human Bacterial Vaccine Tier 1, Tier 2, and Tier 3
5 Human Bacterial Vaccine Market Size by Type
5.1 Global Human Bacterial Vaccine Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Human Bacterial Vaccine Revenue by Type (2020-2031)
5.3 Global Human Bacterial Vaccine Revenue Market Share by Type (2020-2031)
6 Human Bacterial Vaccine Market Size by Application
6.1 Global Human Bacterial Vaccine Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Human Bacterial Vaccine Revenue by Application (2020-2031)
6.3 Global Human Bacterial Vaccine Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Emergent BioSolutions
7.1.1 Emergent BioSolutions Comapny Information
7.1.2 Emergent BioSolutions Business Overview
7.1.3 Emergent BioSolutions Human Bacterial Vaccine Revenue and Gross Margin (2020-2025)
7.1.4 Emergent BioSolutions Human Bacterial Vaccine Product Portfolio
7.1.5 Emergent BioSolutions Recent Developments
7.2 Mitsubishi Tanabe Pharma
7.2.1 Mitsubishi Tanabe Pharma Comapny Information
7.2.2 Mitsubishi Tanabe Pharma Business Overview
7.2.3 Mitsubishi Tanabe Pharma Human Bacterial Vaccine Revenue and Gross Margin (2020-2025)
7.2.4 Mitsubishi Tanabe Pharma Human Bacterial Vaccine Product Portfolio
7.2.5 Mitsubishi Tanabe Pharma Recent Developments
7.3 Bayer
7.3.1 Bayer Comapny Information
7.3.2 Bayer Business Overview
7.3.3 Bayer Human Bacterial Vaccine Revenue and Gross Margin (2020-2025)
7.3.4 Bayer Human Bacterial Vaccine Product Portfolio
7.3.5 Bayer Recent Developments
7.4 GSK
7.4.1 GSK Comapny Information
7.4.2 GSK Business Overview
7.4.3 GSK Human Bacterial Vaccine Revenue and Gross Margin (2020-2025)
7.4.4 GSK Human Bacterial Vaccine Product Portfolio
7.4.5 GSK Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Human Bacterial Vaccine Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Human Bacterial Vaccine Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 Merck
7.6.1 Merck Comapny Information
7.6.2 Merck Business Overview
7.6.3 Merck Human Bacterial Vaccine Revenue and Gross Margin (2020-2025)
7.6.4 Merck Human Bacterial Vaccine Product Portfolio
7.6.5 Merck Recent Developments
7.7 Sanofi
7.7.1 Sanofi Comapny Information
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Human Bacterial Vaccine Revenue and Gross Margin (2020-2025)
7.7.4 Sanofi Human Bacterial Vaccine Product Portfolio
7.7.5 Sanofi Recent Developments
8 North America
8.1 North America Human Bacterial Vaccine Revenue (2020-2031)
8.2 North America Human Bacterial Vaccine Revenue by Type (2020-2031)
8.2.1 North America Human Bacterial Vaccine Revenue by Type (2020-2025)
8.2.2 North America Human Bacterial Vaccine Revenue by Type (2026-2031)
8.3 North America Human Bacterial Vaccine Revenue Share by Type (2020-2031)
8.4 North America Human Bacterial Vaccine Revenue by Application (2020-2031)
8.4.1 North America Human Bacterial Vaccine Revenue by Application (2020-2025)
8.4.2 North America Human Bacterial Vaccine Revenue by Application (2026-2031)
8.5 North America Human Bacterial Vaccine Revenue Share by Application (2020-2031)
8.6 North America Human Bacterial Vaccine Revenue by Country
8.6.1 North America Human Bacterial Vaccine Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Human Bacterial Vaccine Revenue by Country (2020-2025)
8.6.3 North America Human Bacterial Vaccine Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Human Bacterial Vaccine Revenue (2020-2031)
9.2 Europe Human Bacterial Vaccine Revenue by Type (2020-2031)
9.2.1 Europe Human Bacterial Vaccine Revenue by Type (2020-2025)
9.2.2 Europe Human Bacterial Vaccine Revenue by Type (2026-2031)
9.3 Europe Human Bacterial Vaccine Revenue Share by Type (2020-2031)
9.4 Europe Human Bacterial Vaccine Revenue by Application (2020-2031)
9.4.1 Europe Human Bacterial Vaccine Revenue by Application (2020-2025)
9.4.2 Europe Human Bacterial Vaccine Revenue by Application (2026-2031)
9.5 Europe Human Bacterial Vaccine Revenue Share by Application (2020-2031)
9.6 Europe Human Bacterial Vaccine Revenue by Country
9.6.1 Europe Human Bacterial Vaccine Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Human Bacterial Vaccine Revenue by Country (2020-2025)
9.6.3 Europe Human Bacterial Vaccine Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Human Bacterial Vaccine Revenue (2020-2031)
10.2 China Human Bacterial Vaccine Revenue by Type (2020-2031)
10.2.1 China Human Bacterial Vaccine Revenue by Type (2020-2025)
10.2.2 China Human Bacterial Vaccine Revenue by Type (2026-2031)
10.3 China Human Bacterial Vaccine Revenue Share by Type (2020-2031)
10.4 China Human Bacterial Vaccine Revenue by Application (2020-2031)
10.4.1 China Human Bacterial Vaccine Revenue by Application (2020-2025)
10.4.2 China Human Bacterial Vaccine Revenue by Application (2026-2031)
10.5 China Human Bacterial Vaccine Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Human Bacterial Vaccine Revenue (2020-2031)
11.2 Asia Human Bacterial Vaccine Revenue by Type (2020-2031)
11.2.1 Asia Human Bacterial Vaccine Revenue by Type (2020-2025)
11.2.2 Asia Human Bacterial Vaccine Revenue by Type (2026-2031)
11.3 Asia Human Bacterial Vaccine Revenue Share by Type (2020-2031)
11.4 Asia Human Bacterial Vaccine Revenue by Application (2020-2031)
11.4.1 Asia Human Bacterial Vaccine Revenue by Application (2020-2025)
11.4.2 Asia Human Bacterial Vaccine Revenue by Application (2026-2031)
11.5 Asia Human Bacterial Vaccine Revenue Share by Application (2020-2031)
11.6 Asia Human Bacterial Vaccine Revenue by Country
11.6.1 Asia Human Bacterial Vaccine Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Human Bacterial Vaccine Revenue by Country (2020-2025)
11.6.3 Asia Human Bacterial Vaccine Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Human Bacterial Vaccine Revenue (2020-2031)
12.2 SAMEA Human Bacterial Vaccine Revenue by Type (2020-2031)
12.2.1 SAMEA Human Bacterial Vaccine Revenue by Type (2020-2025)
12.2.2 SAMEA Human Bacterial Vaccine Revenue by Type (2026-2031)
12.3 SAMEA Human Bacterial Vaccine Revenue Share by Type (2020-2031)
12.4 SAMEA Human Bacterial Vaccine Revenue by Application (2020-2031)
12.4.1 SAMEA Human Bacterial Vaccine Revenue by Application (2020-2025)
12.4.2 SAMEA Human Bacterial Vaccine Revenue by Application (2026-2031)
12.5 SAMEA Human Bacterial Vaccine Revenue Share by Application (2020-2031)
12.6 SAMEA Human Bacterial Vaccine Revenue by Country
12.6.1 SAMEA Human Bacterial Vaccine Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Human Bacterial Vaccine Revenue by Country (2020-2025)
12.6.3 SAMEA Human Bacterial Vaccine Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.